ATRA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Allogeneic EBV-targeted T-cell PlatformThe allogeneic, EBV-targeted platform provides a differentiated technology base that can support multiple immunotherapy candidates. If clinical development succeeds, this approach could create a repeatable pipeline and broader partnering potential.
Strategic Collaboration Revenue PotentialPartnership-based economics give Atara access to external funding and commercial capabilities while preserving potential milestone and royalty upside. This model can reduce the need to build a full commercial infrastructure before programs reach approval.
Strengthened Board IndependenceAdding an independent director to the Audit Committee supports oversight of financial reporting, controls and capital allocation. Stronger governance is particularly valuable for a clinical-stage company managing development risk and reliance on external funding.
Bears Say
Sharp Revenue DeteriorationThe steep TTM revenue decline indicates that reported collaboration-related income is not recurring or stable. Reduced revenue visibility makes it harder to fund development internally and increases dependence on milestones, new partnerships or capital raises.
Persistently Negative Shareholders' EquityNegative equity signals a structurally weak balance sheet and limits financial flexibility. With debt present and assets relatively modest, Atara may have less capacity to absorb setbacks and may need external financing to sustain operations.
Ongoing Cash Burn And Funding RiskPersistent negative operating and free cash flow shows that the business is not self-funding its research and development activities. Continued cash consumption raises the likelihood of additional financing, dilution or reduced investment in the pipeline.
Atara Biotherapeutics News
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is CHF75.74M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Aug 12, 2026. The company reported -CHF0.257 earnings per share for the quarter, missing the consensus estimate of -CHF0.253 by -CHF0.004.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -0.11.
How many shares outstanding does Atara Biotherapeutics have?
Currently, no data Available
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -CHF0.257 in its last earnings report, missing expectations of -CHF0.253. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Currently, no hedge funds are holding shares in CH:ATRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF12.45 (― Upside)
CHF12.45 (― Upside)
Insider Transactions
Sold Shares
Worth $40.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.03%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.